Kerala Ayurveda Limited reported a consolidated net loss of ₹20.65 crore for the financial year ended March 31, 2026, widening from a loss of ₹15.39 crore in the previous year. Revenue from operations for the year rose to ₹1,311.46 crore from ₹1,203.34 crore in FY25. The board approved the audited financial results for the quarter and year ended March 31, 2026, during a meeting held on May 25, 2026. The company submitted newspaper clippings of the extract of these audited financial results to the Bombay Stock Exchange on May 27, 2026, confirming publication in the Financial Express and Deepika.

Financial Performance

For the quarter ended March 31, 2026, the company reported a consolidated net loss of ₹9.16 crore, compared to a loss of ₹16.46 crore in the same period last year. Total income for the quarter stood at ₹366.43 crore. On a standalone basis, the net loss for FY26 was ₹14.74 crore, compared to ₹13.78 crore in the previous year, with total income increasing to ₹1,034.20 crore from ₹778.61 crore.

Auditor Appointments

The board appointed Mr. Alphonse Scaria as the Internal Auditor for FY 2026-27. Additionally, M/s. SLR & Associates, Kochi, was appointed as the Cost Auditor for the same period. These appointments were made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Auditor's Report

M/s. G. Joseph & Associates, Chartered Accountants, the statutory auditors, issued an audit report with an unmodified opinion on the standalone and consolidated financial results. However, the auditors drew attention to significant trade receivables due from the company's subsidiaries, noting that a substantial portion has been outstanding for more than six months. Management represented that these amounts are fully recoverable, and no provision for expected credit loss was recognised.

The trading window for dealing in the company's securities, which closed on March 31, 2026, will remain shut until 48 hours after the financial results are made public.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE817B01025/843d58ac-4cc1-4d1e-8e7a-23ac38d171dc.pdf

Kerala Ayurveda Limited has received notification from BSE Limited regarding the rejection of its waiver application for a regulatory fine of ₹5,31,000. The rejection was communicated via email on April 16, 2026, marking the end of the company's attempt to seek relief from the penalty imposed by the stock exchange.

Fine Details and Background

The fine was originally imposed by BSE on August 29, 2025, for non-compliance with board composition requirements under Regulation 17(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The violation period extended from October 1, 2024 to June 30, 2025.

Waiver Application Timeline

Kerala Ayurveda had filed a waiver application with BSE on September 9, 2025, seeking relief from the imposed fine. However, after approximately seven months of consideration, BSE rejected the application on April 16, 2026.

Financial Impact and Company Response

Despite the rejection of its waiver application, Kerala Ayurveda had already remitted the fine amount to BSE Limited under protest on March 10, 2026. The company has indicated that apart from the payment of the fine, there are no other material financial implications arising from this regulatory action.

Regulatory Compliance Disclosure

The company has fulfilled its disclosure obligations under Regulation 30 read with Schedule III of the Listing Regulations, providing detailed information as required by SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. The disclosure includes comprehensive details about the authority involved, nature of the action, violation specifics, and financial impact assessment.